001     1018556
005     20231213115655.0
024 7 _ |a 10.1111/ene.16040
|2 doi
024 7 _ |a 1351-5101
|2 ISSN
024 7 _ |a 1468-1331
|2 ISSN
024 7 _ |a 10.34734/FZJ-2023-04884
|2 datacite_doi
024 7 _ |a 37584071
|2 pmid
024 7 _ |a WOS:001060540500001
|2 WOS
037 _ _ |a FZJ-2023-04884
082 _ _ |a 610
100 1 _ |a Hennen, Christina
|0 0000-0003-2091-4638
|b 0
|e First author
245 _ _ |a Botulism after intragastric botulinum toxin injections for weight reduction
260 _ _ |a Oxford [u.a.]
|c 2023
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1701839713_18565
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Although-considering the risk-benefit ratio-botulinum neurotoxin A (BoNT/A) is unequivocally recommended to treat severe neurological diseases such as dystonia, this has not yet been determined for its endoscopic intragastric injection aimed at weight reduction in obesity. However, severe adverse effects of intragastric BoNT/A had not yet been reported, prompting some European countries to endorse its (off-label) use and treat patients transnationally. We here present three cases of botulism after intragastric BoNT/A injections for obesity treatment in a Turkish hospital. Patients presented with cranial nerve affection, bulbar symptoms, and descending paresis, and benefited from treatment with BoNT antitoxin and pyridostigmine. We assume that iatrogenic botulism was induced by overdosing in combination with toxin spread via the highly vascularized gastric tissue. Of note, within a few weeks, more than 80 cases of iatrogenic botulism were reported across Europe after identical intragastric BoNT/A injections. These cases demonstrate the risks of BoNT/A injections if they are not applied within the limits of evidence-based medicine. There is a need for international guidelines to define the indication and a safe dosing scheme, especially in the context of medical tourism.Keywords: botulinum toxins; botulism; medical tourism; obesity.
536 _ _ |a 5251 - Multilevel Brain Organization and Variability (POF4-525)
|0 G:(DE-HGF)POF4-5251
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Demir, Seda
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Dafsari, Haidar Salimi
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Wunderlich, Gilbert
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Böll, Boris
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Hüser, Christoph
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Barbe, Michael Thomas
|0 P:(DE-Juel1)131613
|b 6
700 1 _ |a Fink, Gereon Rudolf
|0 P:(DE-Juel1)131720
|b 7
|u fzj
700 1 _ |a Rueger, Maria Adele
|0 P:(DE-HGF)0
|b 8
|e Corresponding author
773 _ _ |a 10.1111/ene.16040
|g Vol. 30, no. 12, p. 3979 - 3981
|0 PERI:(DE-600)2020241-6
|n 12
|p 3979 - 3981
|t European journal of neurology
|v 30
|y 2023
|x 1351-5101
856 4 _ |u https://juser.fz-juelich.de/record/1018556/files/Euro%20J%20of%20Neurology%20-%202023%20-%20Hennen%20-%20Botulism%20after%20intragastric%20botulinum%20toxin%20injections%20for%20weight%20reduction.pdf
856 4 _ |y Published on 2023-08-16. Available in OpenAccess from 2024-08-16.
|u https://juser.fz-juelich.de/record/1018556/files/post-print.docx.pdf
856 4 _ |y Published on 2023-08-16. Available in OpenAccess from 2024-08-16.
|x icon
|u https://juser.fz-juelich.de/record/1018556/files/post-print.gif?subformat=icon
856 4 _ |y Published on 2023-08-16. Available in OpenAccess from 2024-08-16.
|x icon-1440
|u https://juser.fz-juelich.de/record/1018556/files/post-print.jpg?subformat=icon-1440
856 4 _ |y Published on 2023-08-16. Available in OpenAccess from 2024-08-16.
|x icon-180
|u https://juser.fz-juelich.de/record/1018556/files/post-print.jpg?subformat=icon-180
856 4 _ |y Published on 2023-08-16. Available in OpenAccess from 2024-08-16.
|x icon-640
|u https://juser.fz-juelich.de/record/1018556/files/post-print.jpg?subformat=icon-640
856 4 _ |x icon
|u https://juser.fz-juelich.de/record/1018556/files/Euro%20J%20of%20Neurology%20-%202023%20-%20Hennen%20-%20Botulism%20after%20intragastric%20botulinum%20toxin%20injections%20for%20weight%20reduction.gif?subformat=icon
856 4 _ |x icon-1440
|u https://juser.fz-juelich.de/record/1018556/files/Euro%20J%20of%20Neurology%20-%202023%20-%20Hennen%20-%20Botulism%20after%20intragastric%20botulinum%20toxin%20injections%20for%20weight%20reduction.jpg?subformat=icon-1440
856 4 _ |x icon-180
|u https://juser.fz-juelich.de/record/1018556/files/Euro%20J%20of%20Neurology%20-%202023%20-%20Hennen%20-%20Botulism%20after%20intragastric%20botulinum%20toxin%20injections%20for%20weight%20reduction.jpg?subformat=icon-180
856 4 _ |x icon-640
|u https://juser.fz-juelich.de/record/1018556/files/Euro%20J%20of%20Neurology%20-%202023%20-%20Hennen%20-%20Botulism%20after%20intragastric%20botulinum%20toxin%20injections%20for%20weight%20reduction.jpg?subformat=icon-640
909 C O |o oai:juser.fz-juelich.de:1018556
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 7
|6 P:(DE-Juel1)131720
910 1 _ |a UK Köln
|0 I:(DE-HGF)0
|b 8
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5251
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-22
915 _ _ |a Embargoed OpenAccess
|0 StatID:(DE-HGF)0530
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J NEUROL : 2022
|d 2023-10-22
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2023-10-22
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-22
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-22
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J NEUROL : 2022
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-22
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21